"Microgen worked out and proposed for clinical testing four different vaccine prototypes, with two prototypes based on the H5N1 strain of the [bird flu] virus and the other two on the H5N2 strain," Anton Katlinsky said.
He said the company was currently conducting pre-clinical research work on the vaccines and those that proved to be safe for animals would be submitted for clinical testing in March.
"We expect to receive the results from clinical trials by summer this year," Katlinsky said.
Russia registered its first bird flu cases in Siberian fowl last summer and saw the virus spread west of the Urals into its European territory in October. However, no cases of human infection have been reported.
Katlinsky said that if the trials proved positive, Microgen would be ready to produce the necessary number of vaccines for the strain selected by the World Health Organization.
NPO Microgen was founded in 2003, after a merger of 14 leading state enterprises, which were producing traditional and innovational healthcare products.